UBS Group
AARD

UBS Group’s Aardvark Therapeutics AARD Stock Holding History

UBS Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Sell
35,639
-122,249
-77% -$571K ﹤0.01% 6777
2026
Q1 		$595K Buy
157,888
+131,050
+488% +$1.36M ﹤0.01% 5960
2025
Q4 		$352K Sell
26,838
-27,890
-51% -$348K ﹤0.01% 6271
2025
Q3 		$727K Buy
54,728
+2,804
+5% +$31.6K ﹤0.01% 5816
2025
Q2 		$702K Buy
51,924
+37,219
+253% +$384K ﹤0.01% 5737
2025
Q1 		$110K Buy
+14,705
New +$165K ﹤0.01% 6976

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

UBS Group's AARD Position: Q2 2026 in Review

UBS Group reduced its Aardvark Therapeutics (AARD) stake by 77% in Q2 2026, selling an estimated $571K and leaving 35,639 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #6777.

UBS Group first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $727K in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • UBS Group held 35,639 shares of Aardvark Therapeutics worth $205K as of Q2 2026.
  • UBS Group sold 122,249 Aardvark Therapeutics shares in Q2 2026, an estimated $571K.
  • Aardvark Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6777 holding.
  • UBS Group first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Aardvark Therapeutics position peaked at $727K in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.